Lung Transplantation Updates: Broader Indications with a Focus on Pulmonary arterial Hypertension, Zentralblatt für Chirurgie, May 15, 2025.

In their recent open-access article for the Zentralblatt für Chirurgie, Drs.: Szofia Kovacs, Alberto Benazzo, and Peter Jaksch review the latest International Society for Lung and Heart Transplantion (ISHLT) guidelines on lung transplantation, highlighting a major shift toward personalized, inclusive care. Beyond the underlying lung disease, transplant decisions now consider age, frailty, comorbidities, and psychosocial […]

Lung Transplantation Updates: Broader Indications with a Focus on Pulmonary arterial Hypertension, Zentralblatt für Chirurgie, May 15, 2025. Read Post »

Timing Matters: When Should Pulmonary Arterial Hypertension Patients Be Referred for Lung Transplantation? Current Opinion in Pulmonary Medicine, July 1 2025 edition

Early referral for lung transplantation can be life-saving for people with pulmonary arterial hypertension (PAH). In this important review, van der Ploeg et al. explore when and how patients across major respiratory diseases especially Pulmonary Arterial Hypertension should be referred for transplant evaluation. As medical therapies continue to improve, the urgency and timing of referral

Timing Matters: When Should Pulmonary Arterial Hypertension Patients Be Referred for Lung Transplantation? Current Opinion in Pulmonary Medicine, July 1 2025 edition Read Post »

The Alliance for Pulmonary Hypertension Joins European Patients’ Forum (EPF) to Help Shape the Future of Patient Advocacy in Europe

Introduction The European Patients’ Forum (EPF) is a leading umbrella organisation that represents the collective interests of patient organisations across Europe. With a strong focus on equity, patient-centred care, and meaningful involvement in health policy and systems, the European Patients’ Forum brings together diverse patient voices to influence European health debates and decision-making. The organisation

The Alliance for Pulmonary Hypertension Joins European Patients’ Forum (EPF) to Help Shape the Future of Patient Advocacy in Europe Read Post »

UK-wide study validates the digital version of the emPHasis-10 QOL questionnaire for pulmonary arterial hypertension patients, European Respiratory Journal, May 2025

The emPHasis-10 questionnaire, designed to reflect that lived experience, has long been a trusted tool in both clinics and studies but until now, it was only available on paper. In a new UK-wide study, researchers led by Dr. Joseph Newman and colleagues tested the first digital version of emPHasis-10 using the Atom5™ smartphone app. Their

UK-wide study validates the digital version of the emPHasis-10 QOL questionnaire for pulmonary arterial hypertension patients, European Respiratory Journal, May 2025 Read Post »

Defining “patient engagement” and distinguishing between individual empowerment and systemic partnership and advocacy, Sara Riggae, May 20 2025

Sarah Riggae is a researcher and educator who suffers from Parkinson’s disease,  In a recent article on her blog she defines what is meant by “patient engagement” and distinguishes between “primary” and “secondary” engagement.  Short summary: Primary Patient Engagement focuses on individual patient empowerment in their own healthcare journey. This includes: It’s essentially about patients having

Defining “patient engagement” and distinguishing between individual empowerment and systemic partnership and advocacy, Sara Riggae, May 20 2025 Read Post »

10-year Data on Oral Selexipag: Long-Term Survival, Safety, and Dosing Insights in Pulmonary Arterial Hypertension (PAH), oral session at ISHLT congress, April 29, 2025 

Selexipag is an oral selective IP prostacyclin receptor agonist. This study, presented during an oral session at the International Society for Heart and Lung Transplant (ISHLT) congress on April 29, 2025, provides the longest follow-up data available for any pulmonary arterial hypertension therapy, tracking 574 patients originally randomized to selexipag in the GRIPHON trial, with

10-year Data on Oral Selexipag: Long-Term Survival, Safety, and Dosing Insights in Pulmonary Arterial Hypertension (PAH), oral session at ISHLT congress, April 29, 2025  Read Post »

Survey uncovers significant emotional and social impacts beyond traditional medical outcomes for women with pulmonary arterial hypertension, Healio, May 19, 2025

Isabella Hornick’s article, “ Women with Pulmonary Arterial Hypertension Report Struggles with Family Planning and Caregiver Needs”, published by Healio on May 19, 2205, reports on comprehensive survey conducted on 275 women with pulmonary arterial hypertension aged 21-50 from the U.S., U.K., Canada, and Germany. The average age of the included women differed at PAH

Survey uncovers significant emotional and social impacts beyond traditional medical outcomes for women with pulmonary arterial hypertension, Healio, May 19, 2025 Read Post »

Cereno Scientific receives endorsement from the US Food and Drug Administration for their Phase IIb trial of CS1 in pulmonary arterial hypertension

The investigational drug CS1 aims to reverse the pathological vascular remodeling of the small pulmonary arteries. A successful Phase IIa trial was concluded in 2024 (see our article here). Insights into the long-term use of CS1 are being gathered in an expanded access program with 10 patients from the Phase IIa trial. Preparations are currently

Cereno Scientific receives endorsement from the US Food and Drug Administration for their Phase IIb trial of CS1 in pulmonary arterial hypertension Read Post »

US Food and Drug Administration approves YUTREPIA, a treprostinil inhalation powder for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease

Yutrepia is a dry powder formulation of treprostinil, a prostacyclin analog. It is designed to enhance deep-lung delivery with an easy-to-use device requiring low inspiratory effort. Yutrepia was was tentatively approved by the Food and Drug Administration last year (see our article here), but the agency was waiting for regulatory exclusivity of a competing product

US Food and Drug Administration approves YUTREPIA, a treprostinil inhalation powder for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease Read Post »

Researchers at Imperial College London and Apollo Therapeutics are developing a potential treatment for pulmonary arterial hypertension, David Silverman, Imperial College New, May 5, 2025

Imperial College London is working with Apollo Therapeutics to develop a prospective monoclonal antibody treatment for pulmonary arterial hypertension (PAH). The potential treatment is based on a protein that was identified in original research by the university, and is currently undergoing a proof of concept trial at Hammersmith Hospital, part of Imperial College Healthcare NHS Trust. To

Researchers at Imperial College London and Apollo Therapeutics are developing a potential treatment for pulmonary arterial hypertension, David Silverman, Imperial College New, May 5, 2025 Read Post »

PVRI International Conference 2025 report, Navneet Singh, Katarina Zeder, Pulmonary Circulation, May 1, 2025

An editorial titled “PVRI International Conference 2025: Embracing Heterogeneity”, published in Pulmonary Circulation on May 1, 2025, summarizes the 2025 PVRI International Conference held in Rio de Janeiro, Brazil. The four-day gathering brought together experts from 25 countries across 5 continents to discuss advances in early diagnosis, risk stratification, and treatment approaches for various forms

PVRI International Conference 2025 report, Navneet Singh, Katarina Zeder, Pulmonary Circulation, May 1, 2025 Read Post »

Comparative Analysis of Survival in Pulmonary Arterial Hypertension for Patients Treated with Selexipag in Clinical Practice (EXPOSURE Study), Drugs-Real World Outcomes, April 30, 2025

The EXPOSURE study compared survival rates between pulmonary arterial hypertension (PAH) patients newly treated with selexipag versus other pulmonary arterial hypertension-specific therapies. Survival analyses in EXPOSURE suggest a reduced risk of mortality among the cohort of patients newly initiated on selexipag compared with the modelled cohort newly initiated with other pulmonary arterial hypertension-specific therapies. Further

Comparative Analysis of Survival in Pulmonary Arterial Hypertension for Patients Treated with Selexipag in Clinical Practice (EXPOSURE Study), Drugs-Real World Outcomes, April 30, 2025 Read Post »

“Beyond Survival: 11 Years, 2 Lung Transplants, and the Quiet Miracle of Breathing”, Alena Adarbehova

Alena’s journey transcends ordinary resilience. After battling pulmonary hypertension for a decade, surviving two double lung transplants, and undergoing over 200 photopheresis sessions, she now embraces life with just 34% lung function—yet lives it fully. Her story bridges cultures, identities, and the profound gift of donated organs. As she marks 11 years since her first

“Beyond Survival: 11 Years, 2 Lung Transplants, and the Quiet Miracle of Breathing”, Alena Adarbehova Read Post »

Expert Consensus on Lung Transplantation for Pulmonary Arterial Hypertension Patients, Pulmonary Circulation, April 23, 2025

Globally, over 4,500 lung transplants are performed annually. Pulmonary Arterial Hypertension represents a unique transplantation indication because: Given these specific challenges, the authors developed guidelines for managing Pulmonary Arterial Hypertension patients who are lung transplant candidates through a modified Delphi study. The expert panel reached unanimous consensus on several key aspects of lung transplantation for

Expert Consensus on Lung Transplantation for Pulmonary Arterial Hypertension Patients, Pulmonary Circulation, April 23, 2025 Read Post »

Exploring the relationship between sleep difficulties, worry, mood and health-related quality of life in adults living with pulmonary hypertension, a study by researchers at the University of Sheffield, UK

Sleep difficulties are commonly reported by individuals living with pulmonary hypertension (PH); however, there is limited research examining their impact. In other chronic health conditions, sleep problems can affect health-related quality of life and mental wellbeing, potentially increasing the likelihood of experiencing anxiety and low mood. Establishing this relationship in adults with pulmonary hypertension could

Exploring the relationship between sleep difficulties, worry, mood and health-related quality of life in adults living with pulmonary hypertension, a study by researchers at the University of Sheffield, UK Read Post »

Mental Health Awareness Week in the UK (12-18 May): Discover Support Resources from the UK Pulmonary Hypertension Association for Patients and Families

This week (12th-18th May) is Mental Health Awareness Week in the UK. Over the years the UK pulmonary hypertension association, PHA UK, has built up a range of services and resources to help patients that are struggling with anxiety, depression, or general mental wellbeing, you can find all the details at here.

Mental Health Awareness Week in the UK (12-18 May): Discover Support Resources from the UK Pulmonary Hypertension Association for Patients and Families Read Post »

Algorithm provides offers a noninvasive, point-of-care option for detecting pulmonary hypertension, Pulmonary Hypertension News, May 12, 2025

Early diagnosis of pulmonary hypertension has become critical now that effective treatment options exist. A study has shown that Corvista Health’s machine-learned algorithm can accurately diagnose pulmonary hypertension in a non-invasive way by assessing the elevation of mean pulmonary arterial pressure (mPAP). This system could potentially transform the approach to pulmonary hypertension diagnosis as a

Algorithm provides offers a noninvasive, point-of-care option for detecting pulmonary hypertension, Pulmonary Hypertension News, May 12, 2025 Read Post »

A pivotal study is evaluating the validity of a non invasive diagnostic test for pulmonary hypertension as a possible alternative to right heart catheterization

A pivotal study is evaluating a non-evasive device, the Cardiac Performance System, (CPS), for pulmonary hypertension (PH) to reduce reliance on right heart catheterization. The study will compare the measurements obtained with the Cardiac Performance System with those obtained through right heart catheterization, the current gold-standard test used to measure pulmonary artery pressure. If validated,

A pivotal study is evaluating the validity of a non invasive diagnostic test for pulmonary hypertension as a possible alternative to right heart catheterization Read Post »

The importance of respectful language to enhance care, Joint Statement by the Association of Cardiovascular Nurses & Allied Professions (ACNAP), the ESC Patient Forum & the ESC Advocacy Committee, European Journal of Cardiovascular Nursing, April 11, 2025

This statement highlights the vital role of respectful and inclusive language in cardiovascular care. It emphasizes that the way healthcare professionals communicate can significantly influence patient experiences, trust, engagement, treatment adherence, and overall health outcomes. Language that is stigmatizing, dismissive, or judgmental – whether international or unconscious – can cause harm, reinforce inequalities, and discourage

The importance of respectful language to enhance care, Joint Statement by the Association of Cardiovascular Nurses & Allied Professions (ACNAP), the ESC Patient Forum & the ESC Advocacy Committee, European Journal of Cardiovascular Nursing, April 11, 2025 Read Post »

“Global Voices, One Mission: Amplify the Beat” – our motto for the 2025 edition of World Pulmonary Hypertension Day, May 5

Since its inception in 2012, World Pulmonary Hypertension Day (May 5th) has evolved into a powerful global movement uniting patients, caregivers, healthcare professionals, and advocates across continents. What began as a coordinated effort to raise awareness about this rare and serious condition has grown into an international platform for education, advocacy, and community building. World

“Global Voices, One Mission: Amplify the Beat” – our motto for the 2025 edition of World Pulmonary Hypertension Day, May 5 Read Post »

TRANSLATE »
Scroll to Top